|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.37 EUR | -0.10% |
|
+9.20% | +88.31% |
| 13/12 | Bayer Wins EU Panel's Recommendation for Eye Disease Drug's New Indication | MT |
| 12/12 | BAYER AG : Berenberg reiterates its Neutral rating | ZD |
| Capitalization | 35.79B 42.02B 33.44B 31.46B 57.92B 3,806B 63.27B 390B 151B 1,794B 158B 154B 6,545B | P/E ratio 2025 * |
121x | P/E ratio 2026 * | 14.8x |
|---|---|---|---|---|---|
| Enterprise value | 67.62B 79.37B 63.16B 59.43B 109B 7,189B 120B 737B 286B 3,389B 298B 292B 12,363B | EV / Sales 2025 * |
1.48x | EV / Sales 2026 * | 1.41x |
| Free-Float |
100% | Yield 2025 * |
0.31% | Yield 2026 * | 1.4% |
Last Transcript: Bayer AG
| 1 day | -0.10% | ||
| 1 week | +9.20% | ||
| Current month | +19.30% | ||
| 1 month | +25.15% | ||
| 3 months | +29.57% | ||
| 6 months | +30.73% | ||
| Current year | +88.31% |
| 1 week | 33.82 |  | 37.14 |
| 1 month | 26.64 | | 37.14 |
| Current year | 18.38 | | 37.14 |
| 1 year | 18.38 | | 37.14 |
| 3 years | 18.38 | | 65.66 |
| 5 years | 18.38 | | 67.99 |
| 10 years | 18.38 | | 123.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 59 | 01/06/2023 |
| Director of Finance/CFO | 56 | 01/06/2018 | |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/02/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Paul Achleitner
BRD | Director/Board Member | 69 | 01/04/2002 |
André van Broich
BRD | Director/Board Member | 55 | 01/04/2012 |
| Director/Board Member | 66 | 01/04/2022 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 9.77% | 0 M€ | -.--% | - |
| 4.28% | 962 M€ | -.--% | - |
| 4.1% | 1 M€ | +54.47% | - |
| 4.1% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.10% | +9.20% | +80.27% | -30.49% | 42.02B | |
| +1.80% | +1.70% | +31.34% | +179.78% | 920B | |
| +0.75% | +4.78% | +44.68% | +18.97% | 510B | |
| -0.29% | -1.22% | +28.95% | +35.08% | 395B | |
| -0.35% | +1.90% | +23.99% | +4.55% | 340B | |
| -1.12% | -1.09% | +27.21% | +18.45% | 278B | |
| -0.45% | -1.48% | +19.80% | +24.22% | 254B | |
| +1.30% | +0.58% | -0.94% | -7.96% | 249B | |
| +0.45% | +3.73% | -59.06% | -29.63% | 224B | |
| +0.11% | -3.68% | +15.94% | +14.80% | 171B | |
| Average | -0.04% | +1.41% | +21.22% | +22.78% | 338.4B | |
| Weighted average by Cap. | -0.04% | +1.24% | +22.59% | +57.45% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 45.69B 53.63B 42.68B 40.15B 73.93B 4,858B 80.76B 498B 193B 2,290B 201B 197B 8,354B | 46.01B 54.01B 42.98B 40.44B 74.44B 4,892B 81.33B 502B 195B 2,306B 203B 198B 8,412B |
| Net income | 633M 743M 591M 556M 1.02B 67.32B 1.12B 6.9B 2.68B 31.73B 2.79B 2.73B 116B | 2.59B 3.04B 2.42B 2.28B 4.19B 276B 4.58B 28.26B 10.96B 130B 11.42B 11.18B 474B |
| Net Debt | 31.82B 37.35B 29.72B 27.97B 51.49B 3,383B 56.25B 347B 135B 1,595B 140B 137B 5,818B | 29.12B 34.19B 27.21B 25.6B 47.13B 3,097B 51.48B 318B 123B 1,460B 128B 126B 5,325B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/12/25 | 36.44 € | +0.29% | 2,392,939 |
| 11/12/25 | 36.33 € | -0.78% | 3,173,204 |
| 10/12/25 | 36.62 € | +0.84% | 4,057,539 |
| 09/12/25 | 36.31 € | +4.13% | 5,714,411 |
| 08/12/25 | 34.87 € | +4.70% | 4,224,461 |
Delayed Quote Xetra, 13 December 2025 at 07:57 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BAYN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition